You are here:Home-ADCs and PROTACs-PROTAC-NX-2127
NX-2127

Chemical Structure : NX-2127

CAS No.: 2416131-46-7

NX-2127 (NX2127)

Catalog No.: PC-20560Not For Human Use, Lab Use Only.

NX-2127 (NX2127) is a hetero-bifunctional, orally active PROTAC that induces the degradation of BTK and IKZF3 ubiquitination and proteasomal degradation in cells through recruitment of cereblon (CRBN).

Packing Price Stock Quantity
5 mg $258 In stock
10 mg $398 In stock
25 mg $598 In stock
50 mg Get quote
100 mg Get quote

Bulk size, bulk discount!

E-mail: sales@probechem.com

Tech Support: tech@probechem.com

Purity & Documentation Purity: >98% (HPLC) Select Batch:

Biological Activity

NX-2127 (NX2127) is a hetero-bifunctional, orally active PROTAC that induces the degradation of BTK and IKZF3 ubiquitination and proteasomal degradation in cells through recruitment of cereblon (CRBN).
NX-2127 degrades BTK in multiple B cell lymphoma lines with DC50 values in the range of 1-13 nM.
NX-2127 displays efficient cellular degradation yet binds to WT and mutant BTK with affinities that render covalent and noncovalent BTK inhibitors ineffective.
NX-2127 drives cellular ternary complex formation between BTK and CRBN by inducing positive cooperativity in both WT and acquired resistance mutant settings.
NX-2127 induces potent degradation of C481S, T474I, V416L, and L528W-mutant BTK and suppresses activation marker expression on cells harboring these mutations.
NX-2127 demonstrates oral bioavailability across pre-clinical species and shows robust tumor growth inhibition in WT and mutant mouse models of lymphoma upon once daily PO dosing.

Physicochemical Properties

M.Wt 719.85
Formula C39H45N9O5
Appearance Solid
CAS No.
Storage
Solide Powder
-20°C 12 Months; 4°C 6 Months
In Solvent
-80°C 6 Months; -20°C 6 Months
Shipping
Solubility

10 mM in DMSO

Chemical Name/SMILES

2-Pyrazinecarboxamide, 3-[[4-[1-[[(3S)-1-[2-(2,6-dioxo-3-piperidinyl)-2,3-dihydro-1,3-dioxo-1H-isoindol-5-yl]-3-pyrrolidinyl]methyl]-4-piperidinyl]phenyl]amino]-5-(1-piperidinyl)-

References

1. Jeffrey T. Mihalic, et al. Cancer Res (2023) 83 (7_Supplement): 3423.

Copyright © 2022 probechem.com. All Rights Reserved. probechem Copyright

Contact Us sales@probechem.com

Bulk Inquiry

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • *Additional Information:

Get Quote

* Indicates a Required FieldYour information is safe with us.

  • *Product name:
  • *Applicant name:
  • *Email address:
  • *Organization name:
  • *Requested quantity:
  • *Country:
  • Additional Information: